Log inSign up
Pharma-Marketing.comPharma-Marketing.com
  • Industry
  • Digital Health & AI
  • Channels
  • People
  • Agencies
  • Glossary
Log inSign up
  • Terms of Service
  • Privacy Policy
  • Cookie settings
  • Imprint
Pharma-Marketing.com


All rights reserved.

We use AI tools in the creation of certain content.

Pharma Marketing

Data-privacy settings

We use cookies to improve our website and services. They help us understand how visitors use our website. Some cookies are required for the website to function. These are marked as “essential” in the details.

AcceptEssential cookie
NameData-privacy settings
ProviderPharma-Marketing.com
PurposeStores these privacy settings in your browser.
Privacy policyPrivacy policy
Cookiespm_data_privacy
Cookie expiration180 days
Accept
NameGoogle Analytics
ProviderGoogle LLC
PurposeCookies by Google are used for website analytics. Generates statistical data on how the visitor uses the website.
Privacy policyPrivacy policy
Cookies_ga, _gat, _gid
Cookie expiration2 Years
Accept
NameGoogle Ads
ProviderGoogle LLC
PurposeCookies by Google Ads are used for advertising and targeting purpose.
Privacy policyPrivacy policy
Cookies__gsas, __gpi, __gpi_optout, NID, DSID, test_cookie, id, __gads
Cookie expiration2 Years
Accept
NameFacebook
ProviderFacebook Inc.
PurposeCookies by Facebook are used for advertising and marketing activities. Generates statistical data on how the visitor uses the website.
Privacy policyPrivacy policy
Cookies_fbp, fr
Cookie expiration2 Years
Accept
NameMicrosoft Clarity
ProviderMicrosoft Corporation
PurposeCookies by Microsoft Clarity are used for website analytics, heatmaps, and session recordings. They help us understand how visitors interact with our website so we can improve usability and performance.
Privacy policyPrivacy policy
Cookies_clck, _clsk, CLID, ANONCHK, MR, MUID, SM
Cookie expirationUp to 1 Year
© Image modified: Valerio Therapeutics

Monday, August 24, 2026

Valerio Therapeutics signs agreement to acquire Etherna

Valerio Therapeutics has signed definitive agreements to acquire all shares and voting rights of Etherna Immunotherapies. The transaction values Etherna at an enterprise value of €30 million on a debt-free, cash-free basis. At the same time, the Villejuif-based biotech priced a €40.25 million private investment in public equity financing.

The planned acquisition is intended to strengthen Valerio’s position in targeted RNA therapeutics. Etherna contributes platforms in mRNA, lipid nanoparticles and manufacturing capabilities up to GMP grade, while Valerio points to its own cell-targeting technologies. The combined company aims to support development of RNA medicines for tissues beyond the liver.

Deal structure and financing

The consideration is structured as a cash component and a share component. The cash part will be funded by the PIPE financing. The share component requires approval by Valerio shareholders at an extraordinary general meeting, expected to be held around October 6, 2026.

Valerio said irrevocable voting undertakings have already been obtained from existing shareholders representing more than 70 percent of voting rights. Shares issued as consideration for the contribution of Etherna shares will be valued at the same subscription price as the new shares issued in the financing.

The PIPE consists of 68,220,333 new ordinary shares at €0.59 per share. The price represents a 25 percent discount to the three-day volume-weighted average price before pricing. Admission of the new shares to trading on Euronext Growth Paris is expected on August 26, 2026.

Existing shareholders take part

Existing investors participated in the financing. Artal International SCA subscribed for €18.0 million, Financière de la Montagne for €7.0 million and Saint James Luxembourg for €1.0 million. Artal International SCA and Financière de la Montagne, which are board members or represented on Valerio’s board, did not vote on the financing at the board meeting, according to the company.

After settlement and delivery of the new shares, Valerio’s share capital is expected to amount to €5,676,686.34, divided into 567,668,634 ordinary shares. A shareholder holding 1 percent before the financing and not participating would hold 0.88 percent afterwards on an illustrative basis.

Use of proceeds and strategic rationale

Valerio plans to use the net proceeds, together with existing cash and cash equivalents, to finance the cash portion of the acquisition, advance VTX-001, VTX-002 and VTX-003, and support IND-enabling work for VTX-001. Funds are also intended for the integration of Etherna, including investment in GMP manufacturing capacity at the Niel site.

Based on its current operating plan, the company expects available resources to cover planned operating expenses and capital expenditure needs for at least 18 months after the financing closes. Valerio noted that this estimate depends on development progress, the integration of Etherna and potential additional cash requirements.

The transaction is designed to bring together nucleic acid chemistry, LNP delivery and targeting technologies in an integrated biotech platform. For Valerio, the focus is on improving the delivery of RNA-based medicines to a broader set of tissues.

Advertisement

Only a few physicians log in to your website?

Advertisement

A login that sets a new standard for authenticating HCPs and equips your marketing team with everything they need to successfully promote Rx-products. Learn more on DocID.pro


Stay up to date!

Subscribe to our free Pharma-Marketing-Newsletter.


A Partner For Successful Marketing in Pharma & Healthcare

Advertisement

8awake, the specialized agency for pharma and healthcare marketing, supports you with the successful development and execution of winning campaign activities in healthcare.

Leading providers in pharma and healthcare marketing

Sponsored
  • MINTT Digital
  • 8awake
  • MINTT Digital

  • 8awake

    The leading Healthcare & Pharma-Marketing-Agency

Looking for a new partner in pharma and healthcare marketing?

Visit our agency finder

Copyright 2026 Pharma-Marketing.com.